Why do you lose weight on Mounjaro?

Two receptors, one injection: why the dual mechanism matters

Most GLP-1 medicines work by mimicking a single gut hormone released after eating. Tirzepatide does something different. It activates both the GLP-1 receptor and the GIP receptor, the latter being a second incretin hormone involved in appetite signalling and fat-cell regulation. Stimulating both pathways at once appears to produce a more pronounced effect on hunger than targeting either alone.

In practical terms, the brain receives stronger and more sustained signals that the body has eaten enough. Appetite falls, not through willpower, but because the hormonal environment has shifted. As the NHS medicines page for tirzepatide explains, the medicine belongs to a class called dual GIP and GLP-1 receptor agonists, and is the only member of that class currently licensed in the UK for weight management. That distinction is clinically meaningful: it is why tirzepatide's trial results differ from those of GLP-1-only options. If you want more detail on how tirzepatide compares to other treatments, our overview covers the landscape.

None of this is instant, and the effect builds gradually as the dose increases. The starter dose of 2.5 mg exists mainly to let the body adjust; the therapeutic work happens at higher doses, reached over several months under prescriber guidance.

Gastric emptying, satiety and what changes at mealtimes

One of the most tangible effects people notice is that they feel full faster. Tirzepatide slows gastric emptying, the rate at which food moves from the stomach into the small intestine. When that process is unhurried, stretch receptors in the stomach wall signal fullness to the brain for longer after a meal. The result is that portions naturally shrink without conscious restriction.

This is not the same as suppressing hunger through stimulants or creating an artificial energy deficit by other means. The change is rooted in how the gut and brain communicate. Calorie intake falls because appetite genuinely reduces, and most people find they are simply not as interested in food between meals. That said, the medicine works best alongside a reduced-calorie diet and regular activity, this is part of the licensed indication and part of what a prescriber will discuss with you. Our guide on making the most of treatment covers the lifestyle side in more detail.

It is worth knowing that the response varies between individuals. Some people see early changes within the first few weeks; others notice the shift more clearly after a dose increase. When weight loss tends to start is a question with a more nuanced answer than most expect.

What the clinical trial data tell us, and what they don't

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes across 72 weeks. Those on the 15 mg dose lost around 20–21% of body weight on average. NICE's appraisal noted that indirect comparisons with semaglutide 2.4 mg favoured tirzepatide, a finding later given direct evidence when the SURMOUNT-5 head-to-head trial (also published in the NEJM in 2025) showed tirzepatide producing greater average weight reduction over 72 weeks.

Those numbers deserve a little context. Trial participants followed structured diet and lifestyle support alongside the medicine, and results varied across the group, averages conceal a wide spread of individual responses. The trials also ran for a defined period; what happens to weight over many years, and what the optimal approach to long-term maintenance looks like, is still being studied. Anyone wondering why weight loss sometimes stalls will find that the biology of plateaus is equally well documented. For those who have tried the medicine and feel it hasn't worked as expected, reasons why responses differ is worth reading before drawing conclusions.

As for the cost of treatment, Mounjaro pricing in the UK is a separate consideration from the mechanism, but it is a common follow-on question, so it is worth exploring before starting.

Prescription medicine, clinical oversight and where nume fits

Because tirzepatide produces genuine physiological changes (including effects on blood sugar, gastric function and cardiovascular markers) it requires careful prescribing. Not everyone is a suitable candidate, and the right dose for a given person depends on their health history, other medicines they take, and how they respond at each stage of titration. This is why Mounjaro is prescription-only under UK law.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it arrives. A human clinician, not software, makes the assessment. Our clinical team takes that responsibility seriously, including for people transferring from another provider or asking about a dose increase, where additional evidence is required. If you have general questions before starting, our frequently asked questions cover the process in plain terms. When you're ready to take the next step, speak to our prescribers through a free consultation.